Although we follow an evidence-based approach for all conditions, we also offer enrollment in clinical trials for those patients with conditions that have limited effective treatments. We are currently enrolling patients with idiopathic pulmonary fibrosis in the GS-US-322-0207 study trial, a global study of a novel humanized monoclonal antibody that binds to LOXL2. This therapy aims to reduce morbidity and mortality from this serious condition. If you wish to discuss research going on at our institution, we welcome the opportunity.
In addition, Thomas Jefferson University is a world-renowned academic medical center that actively engages in cutting edge research related to lung fibrosis and interstitial lung disease. If you would like to either hear more about research or to find out ways to support research at Jefferson please contact Dr. Ross Summer at firstname.lastname@example.org or click the following link to his laboratory webpage